Which type 2 diabetes treatments increase the risk of hypoglycemia (low blood sugar)?

Updated: Sep 12, 2019
  • Author: Osama Hamdy, MD, PhD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print
Answer

A study by Eriksson et al indicated that in patients with type 2 diabetes undergoing second-line treatment, the combination of metformin and sulfonylurea carries a greater risk for severe hypoglycemia, cardiovascular disease, and all-cause mortality than does the combination of metformin and dipeptidyl peptidase-4 inhibitor (DPP4i). [6]

Similarly, a study by Gautier et al found that patients with type 2 diabetes treated with metformin plus insulin secretagogues (such as sulfonylurea or glinide) were more likely to experience hypoglycemia than were those treated with metformin plus DPP4i while starting insulin. Both groups achieved similar glycemic control. [7]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!